Compugen Ltd. Announces Additional Grants from Israel Office of Chief Scientist for Validation Studies of Therapeutic Candidates
Published: Jun 24, 2009
TEL AVIV, Israel--(BUSINESS WIRE)--Compugen Ltd. (NASDAQ:CGEN) announced today that it has been notified by the Office of the Chief Scientist of Israel (the “OCS”) that it will receive grants totaling approximately $400,000 to support the Company’s FPRL1 and TP programs during 2009. These grants are in addition to the $500,000 grant announced earlier this month for support of certain other on-going programs.